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Abstract
For many years, surgery alone was the standard treatment for patients with stage I-IIIA
non-small-cell lung cancer (NSCLC). However, recent studies have demonstrated that adjuvant
chemotherapy provides a survival benefit. The first adjuvant chemotherapy for NSCLC was per-
formed in the 1960s using a key drug known as cyclophosphamide. In the 1980s and early 1990s,
a new anti-cancer drug, cisplatin, was developed. The first meta-analysis of this drug was con-
ducted by the Non-small Cell Lung Cancer Collaborative Group in 1995. This analysis comparing
surgery with surgery plus chemotherapy containing cisplatin produced a hazard ratio of 0.87 and
suggested an absolute benefit of chemotherapy of 5% at 5 years;this difference was not statisti-
cally significant (p0.08). Several clinical trials of adjuvant chemotherapy were planned after the
meta-analysis conducted in 1995, but the efficacy of adjuvant chemotherapy remained a matter
of controversy. However, useful evidence was reported after 2003. The International Adjuvant
Lung Cancer Collaborative Group Trial (IALT) demonstrated a 4.1% improvement in survival for
patients with stage I to III NSCLC. The JBR. 10 trial demonstrated a 15% improvement in 5-year
survival for the adjuvant chemotherapy arm in stage IB or II (excluding T3N0) patients. The Ad-
juvant Navelbine International Trialist Association (ANITA) trial reported that the overall survival
at 5 years improved by 8.6% in the chemotherapy arm and that this survival rate was maintained
at 7 years (8.4%) in stage II and IIIA patients. A meta-analysis based on collected and pooled
individual patient data from the 5 largest randomized trials was conducted by the Lung Adjuvant
Cisplatin Evaluation (LACE). This analysis demonstrated that cisplatin-based adjuvant chemother-
apy improved survival in patients with stage II or III cancer. Alterna-tively, uracil-tegafur has been
developed and tested in Japan. The Japan Lung Cancer Research Group (JLCRG) on Postsurgical
Adjuvant Chemotherapy reported a 5-year overall survival advantage of 11% in the uracil-tegafur
group patients with stage IB cancer. The efficacy of adjuvant chemotherapy with uracil-tegafur
was confirmed in a meta-analysis. In conclusion, the results of phase III trials and a meta-analysis
have confirmed the benefit of adjuvant chemotherapy for resected stage IB, II, and IIIA NSCLC.
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For many years,  surgery alone was the standard treatment for patients with stage I-IIIA non-small-
cell lung cancer (NSCLC).  However,  recent studies have demonstrated that adjuvant chemotherapy 
provides a survival beneﬁt.  The ﬁrst adjuvant chemotherapy for NSCLC was performed in the 1960s 
using a key drug known as cyclophosphamide.  In the 1980s and early 1990s,  a new anti-cancer drug,  
cisplatin,  was developed.  The ﬁrst meta-analysis of this drug was conducted by the Non-small Cell 
Lung Cancer Collaborative Group in 1995.  This analysis comparing surgery with surgery plus chemo-
therapy containing cisplatin produced a hazard ratio of 0.87 and suggested an absolute beneﬁt of che-
motherapy of 5ｵ at 5 years; this diﬀerence was not statistically signiﬁcant (p＝0.08).  Several clinical 
trials of adjuvant chemotherapy were planned after the meta-analysis conducted in 1995,  but the eﬃ-
cacy of adjuvant chemotherapy remained a matter of controversy.  However,  useful evidence was 
reported after 2003.  The International Adjuvant Lung Cancer Collaborative Group Trial (IALT) 
demonstrated a 4.1ｵ improvement in survival for patients with stage I to III NSCLC.  The JBR.  10 
trial demonstrated a 15ｵ improvement in 5-year survival for the adjuvant chemotherapy arm in stage 
IB or II (excluding T3N0) patients.  The Adjuvant Navelbine International Trialist Association 
(ANITA) trial reported that the overall survival at 5 years improved by 8.6ｵ in the chemotherapy arm 
and that this survival rate was maintained at 7 years (8.4ｵ) in stage II and IIIA patients.  A meta-
analysis based on collected and pooled individual patient data from the 5 largest randomized trials was 
conducted by the Lung Adjuvant Cisplatin Evaluation (LACE).  This analysis demonstrated that cispla-
tin-based adjuvant chemotherapy improved survival in patients with stage II or III cancer.  Alterna-
tively,  uracil-tegafur has been developed and tested in Japan.  The Japan Lung Cancer Research 
Group (JLCRG) on Postsurgical Adjuvant Chemotherapy reported a 5-year overall survival advantage 
of 11ｵ in the uracil-tegafur group patients with stage IB cancer.  The eﬃcacy of adjuvant chemo-
therapy with uracil-tegafur was conﬁrmed in a meta-analysis.  In conclusion,  the results of phase III 
trials and a meta-analysis have conﬁrmed the beneﬁt of adjuvant chemotherapy for resected stage IB,  
II,  and IIIA NSCLC.
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ung cancer is the most common cause of death 
from cancer in industrialized countries [1].  
Human lung cancers are divided into 2 major types,  
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small-cell lung cancer and non-small-cell lung cancer 
(NSCLC) [2].  Despite great eﬀorts to improve the 
survival of patients with NSCLC,  satisfactory out-
comes have not been achieved.  Even in early-stage 
NSCLC patients who undergo surgical resections,  
recurrent disease often impairs the clinical outcome.  
The postoperative 5-year survival rate for stage IA 
and IB NSCLC was reported to range from 72ｵ to 
46ｵ in America and European countries [3-5].  In 
Japan,  this value reportedly ranged from 83ｵ to 
60ｵ (Table 1) [6,  7].
　 For many years,  surgery alone was the standard 
treatment for patients with stage I-IIIA NSCLC.  
However,  recent studies have demonstrated that adju-
vant chemotherapy provides a survival beneﬁt in 
patients with resected NSCLC.
　 The purpose of this article was to provide a gen-
eral overview of the evolution of adjuvant chemo-
therapy for resected NSCLC,  with a special emphasis 
on recently reported randomized trials that have 
demonstrated improvements in survival and reductions 
in cancer recurrence with adjuvant chemotherapy.
Earlier Studies from 1980s to 1995
　 The ﬁrst adjuvant chemotherapy for NSCLC was 
performed in the 1960s.  The key drug was cyclophos-
phamide with or without other drugs.  These trials 
failed to prove the eﬀectiveness of adjuvant chemo-
therapy for patients with resected NSCLC.
　 In the 1980s and early 1990s,  multiple studies of 
adjuvant chemotherapy after resection showed con-
ﬂicting results.  In this era,  the development of a new 
anti-cancer drug,  cisplatin,  was the new hope of chemo-
therapy.  The ﬁrst report to prove the eﬃcacy of adju-
vant chemotherapy for resected NSCLC was per-
formed by the Lung Cancer Study Group (LCSG) in 
America.  The LCSG evaluated cyclophosphamide,  
doxorubicin,  and cisplatin (CAP) chemotherapy.  This 
trial randomized 141 patients and compared Bacillus 
Calmette-Guerin (BCG) and levamisole immunother-
apy with postoperative chemotherapy in patients with 
stage II and III (any T3 and/or any N2) adenocarci-
noma and large cell carcinoma after complete surgical 
resection.  Disease-free survival was signiﬁcantly 
prolonged in the group receiving CAP chemotherapy.  
A 6-month delay in the median time to recurrence and 
a 15ｵ survival advantage at 1 year in favor of chemo-
therapy were reported [8].  Of note,  the control 
group in this trial consisted not of patients receiving 
surgery alone,  but of patients administered BCG for 
cancers in the intrathoracic space or levamisole for 
cancers in the oral region.  Another LCSG trial for 
CAP did not show signiﬁcant improvements in overall 
survival or progression-free survival in NSCLC 
patients.
　 In 1992,  a randomized trial with CAP chemo-
therapy was reported in Finland.  One hundred ten 
patients with T1-3N0 (World Health Organization 
[WHO] staging 1981) NSCLC underwent radical 
surgery and were randomized to receive adjuvant 
chemotherapy (n＝54) (CAP for 6 cycles) or no active 
treatment (n＝56).  Seventeen patients (31ｵ) in the 
CAP group and 27 patients (48ｵ) in the control group 
developed a recurrence during the follow-up period (p
＝0.01).  The 5-year survival rate was 67ｵ in the 
chemotherapy group and 56ｵ in the control group (p
＝0.050).  The patients in the chemotherapy group 
who completed the planned treatment had a slightly 
better 5-year survival rate than those who did not 
complete chemotherapy (72.5ｵ vs.  50.3ｵ; p＝0.15).  
Chemotherapy-related gastrointestinal toxicity of 
grade 3 to 4 (WHO) occurred in 63ｵ and was the 
main reason why patients refused further planned 
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Table 1　 The pathological 5-year survival rate (%) for resected NSCLC
Stage Goya [6] Asamura [7] Mountain [3] Van Rens [4]
ⅠA 79.5 83.9 67 63
ⅠB 60.1 66.3 57 46
ⅡA 59.9 61.0 55 52
ⅡB 42.2 47.4 39 33
ⅢA 29.8 32.8 23 19
ⅢB 19.3 29.6 3-7 －
Ⅳ 20.0 23.1 1 －
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therapy [9].
Meta-analysis by the Non-small Cell Lung 
Cancer Collaborative Group in 1995
　 The inconclusive results of the clinical trials led to 
the publication of the ﬁrst meta-analysis,  conducted by 
the Non-small Cell Lung Cancer Collaborative Group,  
in 1995.  This analysis included 9,387 NSCLC 
patients who had undergone complete resections in 52 
randomized clinical trials performed between 1965 
and 1991.  Among the 4,357 patients who were 
included in the analysis,  trials comparing surgery with 
surgery plus chemotherapy containing cisplatin yielded 
a hazard ratio of 0.87,  corresponding to a 13ｵ 
reduction in the risk of death,  and suggested an abso-
lute beneﬁt of chemotherapy of 3ｵ at 2 years and 5ｵ 
at 5 years.  The P-value was 0.08 and,  therefore,  was 
not statistically signiﬁcant [10].  Although the results 
of this meta-analysis had no impact on clinical practice,  
the statistically non-signiﬁcant beneﬁt of adjuvant 
chemotherapy on the 5-year survival rate resulted in 
several new randomized adjuvant studies to determine 
the real beneﬁt of adjuvant chemotherapy.
　 After the above-mentioned meta-analysis by the 
Non-small Cell Lung Cancer Collaborative Group,  
several clinical trials examining adjuvant chemother-
apy were performed.  However,  no survival beneﬁt was 
demonstrated.  Two large studies with negative results 
are described below.
Adjuvant Lung Project Italy (ALPI) Trial
　 The Adjuvant Lung Project Italy (ALPI) trial 
randomized 1,209 patients with stage I,  II,  or IIIA 
NSCLC between 1994 and 1999.  Patients were ran-
domly assigned to receive mitomycin,  vindesine,  or 
cisplatin every 3 weeks for 3 cycles or no treatment.  
After a median follow-up time of 64.5 months,  no 
statistically signiﬁcant diﬀerences in overall survival 
(hazard ratio (HR)＝0.96,  95ｵ conﬁdence interval 
(CI)＝0.81 to 1.13; p＝0.589) or progression-free 
survival (HR＝0.89,  95ｵ CI＝0.76 to 1.03; p＝
0.128) were observed between the 2 patient groups.  In 
the multivariable analysis,  only disease stage and sex 
were associated with survival [11].
Big Lung Trial (BLT)
　 Another study with negative results was the Big 
Lung Trial (BLT) from Great Britain,  which exam-
ined the role of cisplatin-based chemotherapy.  A total 
of 381 patients were randomized to receive chemo-
therapy (192 patients) or no chemotherapy (189 
patients).  Chemotherapy consisted of three 3-week 
cycles of cisplatin/vindesine,  mitomycin/ifosfamide/
cisplatin,  mitomycin/vinblastine/cisplatin or vinorel-
bine/cisplatin.  Chemotherapy was administered before 
surgery in 3ｵ of the patients while 97ｵ received 
adjuvant chemotherapy.  The median patient age was 
61 years,  69ｵ were male,  and 48ｵ had a squamous 
histology.  Twenty-seven percent of the patients had 
stage I cancer,  38ｵ had stage II,  and 26ｵ had stage 
IIIA.  A complete resection was achieved in approxi-
mately 95ｵ of the patients.  After a median follow-up 
period of 34.6 months,  no signiﬁcant diﬀerence 
between the 2 treatment groups in terms of overall 
survival (HR＝1.02,  95ｵ CI＝0.77 to 1.35; p＝
0.90) or progression-free survival (HR＝0.97,  95ｵ 
CI＝0.74 to 1.26; p＝0.81) was observed [12].
　 On the other hand,  reports on adjuvant chemo-
therapy began to appear after 2003.
The International Adjuvant Lung Cancer 
Collaborative Group Trial (IALT)
　 The International Adjuvant Lung Cancer Collabo-
rative Group Trial (IALT) presented their results at 
the Annual Meeting of the American Society of 
Clinical Oncology (ASCO) in 2003.  This trial was the 
largest study of adjuvant chemotherapy that had been 
conducted to date,  and was designed to demonstrate 
an absolute improvement in survival of 5ｵ,  from 
50ｵ to 55ｵ,  at 5 years with adjuvant chemotherapy,  
based on the hypothesis generated in 1995 as a result 
of the meta-analysis.  A total of 1,867 patients with 
pathological stage I,  II,  or III NSCLC underwent 
randomization.  Adjuvant chemotherapy consisted of 
cisplatin for 3 to 4 cycles combined with vindesine,  
vinblastine,  vinorelbine,  or etoposide.  In this trial,  
＞50ｵ of the patients in the treatment group received 
the second-generation combination of cisplatin and 
etoposide.  Approximately one-quarter of the patients 
received postoperative radiotherapy.  At the time of 
publication,  the median follow-up time was 56 months.  
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The survival rate was signiﬁcantly higher in the che-
motherapy group than in the observation group 
(44.5ｵ vs.  40.4ｵ at 5 years; HR＝0.86; 95ｵ CI
＝0.76 to 0.98,  p＜0.03).  The disease-free survival 
rate was also signiﬁcantly higher in the chemotherapy 
group than in the observation group (39.4ｵ vs.  
34.3ｵ at 5 years; HR＝0.83; 95ｵ CI＝0.74 to 
0.94,  p＜0.003).  Seven patients (0.8ｵ) died of che-
motherapy-induced toxic eﬀects [13].
　 At the Annual Meeting of the ASCO in 2008,  the 
results of a long-term follow-up analysis of the 
patients enrolled in the IALT were reported.  The 
median follow-up period was 7.5 years as of the cut-oﬀ 
date of September 1,  2005.  The survival status of 
1,807 patients was known.  The results showed no 
signiﬁcant eﬀect of adjuvant chemotherapy on overall 
survival (HR＝0.91; 95ｵ CI＝0.81 to 1.02; p＝
0.10).  Overall survival was signiﬁcantly diﬀerent 
before and after 5 years.  These results conﬁrmed the 
eﬃcacy of chemotherapy for the ﬁrst 5 years after 
surgery [14].
　 At the Annual Meeting of the ASCO in 2004,  2 
important presentations were made by the National 
Cancer Institute of Canada Clinical Trials Group 
(NCIC CTG) and the Cancer and Leukemia Group B 
(CALGB).
JBR.  10 Trial
　 The NCIC CTG presented the results of an inter-
group trial,  JBR.  10.  This phase III study randomly 
assigned 482 patients with completely resected stage 
IB or II (excluding T3N0) cancer to observation or 
four cycles of cisplatin plus vinorelbine weekly for 16 
weeks.  Forty-ﬁve percent of the patients had patho-
logical stage IB disease and 55ｵ had stage II disease.  
In both groups,  the median age was 61 years,  and 
53ｵ had adenocarcinomas.  Overall survival was sig-
niﬁcantly prolonged in the chemotherapy group,  com-
pared with the observation group (94 vs.  73 months;  
HR＝0.69; 95ｵ CI＝0.52 to 0.91,  p＝0.04),  as was 
relapse-free survival (not reached vs.  46.7 months;  
HR＝0.60; 95ｵ CI＝0.45 to 0.79,  p＜0.001).  A 
15ｵ improvement in 5-year survival favoring adjuvant 
chemotherapy was also observed (69ｵ vs.  54ｵ,  p＝
0.03) [15].
CALGB 9633 Trial
　 The CALGB 9633 trial had evaluated adjuvant 
chemotherapy in patients with completely resected 
stage IB NSCLC.  A total of 344 patients were ran-
domized to receive 4 cycles of adjuvant paclitaxel plus 
carboplatin every 3 weeks versus no further treat-
ment.  The overall survival time was signiﬁcantly lon-
ger in the chemotherapy arm (p＝0.028) with a 12ｵ 
improvement in 4-year survival at a median follow-up 
time of 34 months.  But,  after a median follow-up 
period of 74 months,  the overall survival rates at 5 
years were 60ｵ and 58ｵ for the chemotherapy and 
observation groups,  respectively (HR＝0.83; 90ｵ 
CI＝0.64 to 1.08,  p＝0.125).  An exploratory analy-
sis demonstrated a signiﬁcant survival diﬀerence in 
favor of adjuvant chemotherapy for patients with 
tumors＞4cm in diameter (HR＝0.69; 90ｵ CI＝
0.48 to 0.99,  p＝0.043) [16].
The Adjuvant Navelbine International Trialist 
Association (ANITA) Trial
　 At the Annual Meeting of the ASCO in 2005,  the 
Adjuvant Navelbine International Trialist Association 
(ANITA) trial was presented.  In this prospective 
phase III trial,  840 completely resected stage IB,  II 
or IIIA patients were randomly assigned to receive 4 
cycles of cisplatin plus vinorelbine versus no further 
treatment.  Postoperative radiotherapy was not man-
datory and was given according to the policy at each 
center.  After a median follow-up period of 76 months,  
the median survival was 65.7 months (95ｵ CI＝0.48 
to 0.89) in the chemotherapy group and 43.7 months 
(95ｵ CI＝0.36 to 0.52) in the observation group.  The 
adjusted risk for death was signiﬁcantly reduced 
among the patients assigned to the chemotherapy arm,  
compared with the controls (HR＝0.80; 95ｵ CI＝
0.66 to 0.96,  p＝0.017).  Overall survival at 5 years 
improved by 8.6ｵ in the chemotherapy arm,  and this 
survival rate was maintained at 7 years (8.4ｵ).  In this 
study,  the favorable impact on survival using adjuvant 
chemotherapy was restricted to stage II and IIIA 
patients,  and no beneﬁt was observed among those 
with stage IB cancer [17].
226 Acta Med.  Okayama　Vol.  63,  No.  5Suehisa et al.
4
Acta Medica Okayama, Vol. 63 [2009], Iss. 5, Art. 1
http://escholarship.lib.okayama-u.ac.jp/amo/vol63/iss5/1
The Lung Adjuvant Cisplatin Evaluation 
(LACE) Meta-Analysis
　 The Lung Adjuvant Cisplatin Evaluation (LACE) 
study was presented at the Annual Meeting of the 
ASCO in 2006.  This meta-analysis was based on col-
lected and pooled individual patient data from the 5 
largest randomized trials (ALPI,  ANITA,  BLT,  
IALT and JBR.  10; 4,584 patients) conducted after 
the 1995 NSCLC meta-analysis.  With a median fol-
low-up period of 5.2 years,  the overall HR of death 
was 0.89 (95ｵ CI＝0.82 to 0.96,  p＝0.005),  corre-
sponding to a 5-year absolute beneﬁt from chemo-
therapy of 5.4ｵ.  The beneﬁt varied with stage (test 
for trend,  p＝0.04; HR for stage IA＝1.40; 95ｵ 
CI＝0.95 to 2.06; HR for stage IB＝0.93; 95ｵ CI
＝0.78 to 1.10; HR for stage II＝0.83; 95ｵ CI＝
0.73 to 0.95; and HR for stage III＝0.83; 95ｵ CI＝
0.72 to 0.94).  The eﬀect of chemotherapy did not vary 
signiﬁcantly (test for interaction,  p＝0.11) with the 
associated drugs,  including vinorelbine (HR＝0.80;  
95ｵ CI＝0.70 to 0.91),  etoposide or vinca alkaloid 
(HR＝0.92; 95ｵ CI＝0.80 to 1.07) [18].  When sub-
groups according to age were analyzed (3,269 patients
＜65 years old,  71ｵ; 901 patients 65-69 years old,  
20ｵ; and 414 patientsｧ70 years old,  9ｵ),  no sta-
tistically signiﬁcant interaction (p＝0.26) or test for 
trends (p＝0.29) was observed between age and the 
treatment eﬀect on overall survival.  Similarly,  no 
signiﬁcant diﬀerences in event-free survival were 
observed (p＝0.42) [19].
The Medical Research Council (MRC)  
Meta-Analysis
　 The Medical Research Council (MRC) meta-analy-
sis was reported at the Annual Meeting of the ASCO 
in 2007.  Individual patient data were obtained for 
8147 patients from 30 randomized clinical trials,  of 
which 22 trials examined a cisplatin-based regimen.  
An overall survival beneﬁt for chemotherapy was 
reported (HR＝0.86; 95ｵ CI＝0.81 to 0.93; p＜
0.000001),  with an absolute beneﬁt of 4ｵ (from 60ｵ 
to 64ｵ) at 5 years.  Similar results for recurrence-
free survival and time to distant recurrence were 
obtained [20].
Trials for Uracil-Tegafur in Japan
　Since 2003,  cisplatin-based adjuvant chemotherapy 
for resected NSCLC has provided a signiﬁcant sur-
vival beneﬁt for patients with stage II-III cancer.  As 
an alternative to this treatment and in view of its mild 
toxicity proﬁle,  uracil-tegafur has been developed and 
tested in Japan.  Uracil-tegafur,  an antimetabolite that 
combines tegafur (a ﬂuorouracil [FU] prodrug) and 
uracil in a 1: 4 molar ratio and can be administered 
orally,  has been approved for the treatment of 
patients with resected NSCLC,  and its use in adju-
vant settings has been extensively examined since the 
1980s.
The West Japan Study Group for Lung Cancer 
Surgery (WJSG) study II
　 The second study conducted by the West Japan 
Study Group for Lung Cancer Surgery (WJSG) was 
the ﬁrst trial to conﬁrm a survival beneﬁt of uracil-
tegafur in an adjuvant chemotherapy setting.  This trial 
contained three-arms,  and 323 patients with resected 
p-stage I-III NSCLC were randomly assigned to a 
surgery alone group,  a uracil-tegafur (Uft) alone 
group,  or a cisplatin plus vindesine followed by uracil-
tegafur (CVUft) group.  The overall 5-year survival 
rates were 60.6ｵ for the CVUft group and 64.1ｵ for 
the Uft group,  versus 49.0ｵ for the control group.  
The results of statistical testing among the 3 groups 
yielded a p value of 0.044.  The most favorable ﬁnding 
was the signiﬁcantly better survival obtained in the Uft 
groups compared with the surgery alone group (HR＝
0.55; 95ｵ CI＝0.36 to 0.86; p＝0.022) [21].
　 After this second WJSG study,  uracil-tegafur was 
studied as both a single-agent therapy following sur-
gery [22-26] or following one or more cycles of cis-
platin-based chemotherapy.  The results from these 
trials have been mixed,  with some demonstrating a 
survival beneﬁt [23,  26] and others not [22,  24,  
25].
The Japan Lung Cancer Research Group 
(JLCRG) Study
　 A larger study comparing uracil-tegafur therapy 
versus observation was performed by the Japan Lung 
Cancer Research Group (JLCRG) on Postsurgical 
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Adjuvant Chemotherapy.  A total of 979 patients with 
stage I adenocarcinoma were assigned to receive 
either oral uracil-tegafur for 2 years or observation.  
These patients had either T1 disease (72ｵ) or T2 
disease (28ｵ).  The median follow-up period was 73 
months.  A grade 3 adverse reaction developed in 10 
of the 482 patients (2ｵ),  but no grade 4 adverse 
reactions occurred.  The 5-year overall survival rate 
was 88ｵ in the uracil-tegafur group and 85ｵ in the 
control group (HR＝0.71; 95ｵ CI＝0.52 to 0.98; p
＝0.04).  The 5-year overall survival rate among the 
patients with T2 disease was 85ｵ in the uracil-tega-
fur group and 74ｵ in the control group (HR＝
0.48; 95ｵ CI＝0.29 to 0.81; p＝0.005).  Moreover,  
in the T1 disease subgroup of patients with a tumor 
that was greater than 2cm in diameter,  treatment with 
uracil-tegafur provided a deﬁnite survival beneﬁt (p＝
0.05) [23].
Meta-Analysis for Uracil-Tegafur
　 The eﬃcacy of adjuvant chemotherapy with uracil-
tegafur was conﬁrmed in a meta-analysis of the above-
mentioned 6 trials comparing surgery alone with sur-
gery plus uracil-tegafur.  A total of 2,003 patients 
were eligible.  The most common histologic type was 
adenocarcinoma (1,679 patients,  83.8ｵ).  Most patients 
had p-stage I (1,982 patients,  99.0ｵ).  The median 
follow-up period was 6.44 years.  The survival rates at 
5 and 7 years were signiﬁcantly higher in the surgery 
plus uracil-tegafur group (81.5ｵ and 76.5ｵ,  respec-
tively) than in the surgery alone group (77.2ｵ and 
69.5ｵ,  respectively; p＝0.011 and 0.001,  respec-
tively).  The overall pooled hazard ratio was 0.74,  and 
its 95ｵ CI was 0.61 to 0.88 (p＝0.001) [27].
New Strategies Based on Molecular Markers
　 Accumulating knowledge of molecular oncology is 
enabling us not only to understand the pathogenesis of 
NSCLC but also to predict the sensitivity of tumors 
to anticancer drugs.  In adjuvant settings,  patients 
with excision of repair cross-complementation group 1 
(ERCC1)-negative tumors showed prolonged survival 
compared with patients with ERCC1-positive tumors 
[28].
　 In addition,  epidermal growth factor receptor 
(EGFR) gene mutations have been identiﬁed in 
NSCLC and are signiﬁcantly related to a favorable 
clinical outcome among patients treated with EGFR-
tyrosine kinase inhibitors (EGFR-TKIs) [29-31].  
Moreover,  EGFR status inﬂuenced the eﬀect of adju-
vant chemotherapy with uracil-tegafur [32].  It would 
be of great interest to further examine the eﬃcacy of 
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1995 meta-analysis [10] 1394 I-IIIA CDDP based 0.87 (0.74-1.02) 　NS 5
ALPI [11] 1209 I-IIIA MVP 0.96 (0.81-1.13) 　NS 1
BLT [12] 481 I-IIIA CDDP based 1.02 (0.77-1.35) 　NS －
IALT [13] 1867 I-III CDDP＋Vin 0.86 (0.76-0.98) ＜0.03 4.1
JBR. 10 [15] 482 IB-II CDDP＋VNB 0.69 (0.52-0.91) 　0.04 15
CALGB9633 [16] 344 IB CBDCA＋PTX 0.83 (0.64-1.08)＊ 　NS 2
ANITA [17] 840 IB-IIIA CDDP＋VNB 0.80 (0.66-0.96) 　0.017 8.6
LACE meta-analysis [18] 4584 I-III CDDP based 0.89 (0.82-0.96) 　0.005 5.8
MRC meta-analysis [20] 8147 I-IIIA CDDP based, uft 0.86 (0.81-0.93) ＜0.000001 4
WJSG(II) [21] 323 I-III uft 0.55 (0.36-0.86) 　0.022 15.1
JLCRG [23] 979 I (Ad) uft 0.71 (0.52-0.98) 　0.04 3
Uft meta-analysis [27] 2003 I uft 0.74 (0.61-0.88) 　0.001 4.6
Abbreviations: NSCLC,  non-small-cell lung cancer; C.I.,  conﬁdence interval; CDDP,  Cisplatin; NS,  Not Signiﬁcant; ALPI,  Adjuvant 
Lung Project Italy; MVP,  mitomycin＋vindesin+cisplatin; BLT,  Big Lung Trial; IALT,  International Adjuvant Lung Cancer Collaborative 
Group Trial; Vin,  vinca alkaloid; VNB,  vinorelbine; CALGB,  Cancer and Leukemia Group B; CBDCA,  carboplatin; PTX,  
paclitaxel; ANITA,  Adjuvant Navelbine International Trialist Association; LACE,  Lung Adjuvant Cisplatin Evaluation; MRC,  Medical 
Research Council; WJSG,  West Japan Study Group for Lung Cancer Surgery; uft,  uracil-tegafur; JLCRG,  Japan Lung Cancer Research 
Group; Ad,  Adenocarcinoma ＊90% C.I.
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adjuvant chemotherapy according to the status of 
EGFR mutation.
Concluding Remarks
　 The beneﬁt of adjuvant chemotherapy for resected 
stage IB,  II,  or IIIA NSCLC has been shown based 
on the results of phase III trials,  such as the IALT,  
JBR10,  ANITA and JLCRG studies,  and the meta-
analysis Table 2.  In clinical practice,  however,  the 
5-year survival beneﬁt was only 5ｵ to 10ｵ,  and 
severe adverse reactions were seen in patients receiv-
ing cisplatin.  Further studies examining the value of 
biomarkers for predicting the clinical outcome of 
adjuvant chemotherapy are now being planned.
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